The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Chronic lymphocytic leukemia (CLL) is a type of cancer ... complete blood count and blood cell exam or flow cytometry. During a complete blood count and blood cell exam, also known as peripheral ...

The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. Obe-cel is a CD19-directed genetically modified autologous T cell immunotherapy that ...

These sort of "living drugs"—T-cells modified to expand, recognize and attack cancer cells within the body—offer ... For children with acute lymphoblastic leukemia (ALL), measurable residual ...

Jylamvo was originally approved by the FDA in November 2022 for the treatment of adults with acute lymphoblastic leukemia in conjunction with a combination chemotherapy maintenance regimen, adults ...